[go: up one dir, main page]

CY1119919T1 - Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii-fc kai meθοδοι χρησης αυτων - Google Patents

Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii-fc kai meθοδοι χρησης αυτων

Info

Publication number
CY1119919T1
CY1119919T1 CY20181100182T CY181100182T CY1119919T1 CY 1119919 T1 CY1119919 T1 CY 1119919T1 CY 20181100182 T CY20181100182 T CY 20181100182T CY 181100182 T CY181100182 T CY 181100182T CY 1119919 T1 CY1119919 T1 CY 1119919T1
Authority
CY
Cyprus
Prior art keywords
hybrid polypeptides
methods
chemical
factors viii
chimeric
Prior art date
Application number
CY20181100182T
Other languages
English (en)
Inventor
Jennifer A. Dumont
Susan Low
Alan J. Bitonti
Glenn Pierce
Alvin Luk
Haiyan Jiang
Byron Mckinney
Matt Ottmer
Jurg Sommer
Karen Nugent
Lian Li
Robert Peters
Original Assignee
Bioverativ Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc. filed Critical Bioverativ Therapeutics Inc.
Publication of CY1119919T1 publication Critical patent/CY1119919T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μεθόδους χορήγησης Παράγοντα VIII• μεθόδους χορήγησης χιμαιρικών και υβριδικών πολυπεπτιδίων που περιέχουν Παράγοντα VIII• χιμαιρικά και υβριδικά πολυπτεδία που περιέχουν Παράγοντα VIII• πολυνουκλεοτίδια που κωδικοποιούν τέτοια χιμαιρικά και υβριδικά πολυπεπτίδια• κύτταρα που περιέχουν τέτοια πολυνουκλεοτίδια• και μεθόδους παραγωγής τέτοιων χιμαιρικών και υβριδικών πολυπεπτιδίων με τη χρήση τέτοιων κυττάρων.
CY20181100182T 2009-12-06 2018-02-14 Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii-fc kai meθοδοι χρησης αυτων CY1119919T1 (el)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US26707009P 2009-12-06 2009-12-06
US28505409P 2009-12-09 2009-12-09
US30159210P 2010-02-04 2010-02-04
US36306510P 2010-07-09 2010-07-09
US37311310P 2010-08-12 2010-08-12
US41092910P 2010-11-07 2010-11-07
US41967610P 2010-12-03 2010-12-03
PCT/US2010/059136 WO2011069164A2 (en) 2009-12-06 2010-12-06 Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof

Publications (1)

Publication Number Publication Date
CY1119919T1 true CY1119919T1 (el) 2018-06-27

Family

ID=44115536

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100182T CY1119919T1 (el) 2009-12-06 2018-02-14 Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii-fc kai meθοδοι χρησης αυτων
CY20211100615T CY1124888T1 (el) 2009-12-06 2021-07-07 Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii-fc και μεθοδοι χρησεως αυτων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100615T CY1124888T1 (el) 2009-12-06 2021-07-07 Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii-fc και μεθοδοι χρησεως αυτων

Country Status (30)

Country Link
US (5) US9050318B2 (el)
EP (4) EP3906937A1 (el)
JP (8) JP5903048B2 (el)
KR (1) KR101770849B1 (el)
CN (1) CN102791285A (el)
AU (6) AU2010325787B2 (el)
BR (1) BR112012013502A2 (el)
CA (2) CA2782424C (el)
CO (1) CO6561782A2 (el)
CY (2) CY1119919T1 (el)
DK (1) DK2506868T3 (el)
EA (2) EA025416B1 (el)
ES (2) ES2659888T3 (el)
HR (2) HRP20180135T1 (el)
HU (1) HUE036233T2 (el)
IL (2) IL220204B (el)
LT (1) LT2506868T (el)
ME (1) ME02964B (el)
MX (3) MX336830B (el)
MY (1) MY159135A (el)
NO (1) NO2506868T3 (el)
NZ (2) NZ703153A (el)
PL (2) PL3326643T3 (el)
PT (2) PT2506868T (el)
RS (1) RS56957B1 (el)
SG (3) SG10201408049SA (el)
SI (1) SI2506868T1 (el)
SM (1) SMT201800099T1 (el)
WO (1) WO2011069164A2 (el)
ZA (1) ZA201204874B (el)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
PL2393828T3 (pl) 2009-02-03 2017-06-30 Amunix Operating Inc. Wydłużone rekombinowane polipeptydy i zawierające je kompozycje
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
AU2010325787B2 (en) * 2009-12-06 2016-05-12 Bioverativ Therapeutics Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
KR102110736B1 (ko) * 2011-07-08 2020-05-14 바이오버라티브 테라퓨틱스 인크. Viii 인자 키메라 및 하이브리드 폴리펩타이드, 그리고 이들의 사용 방법
US10656167B2 (en) * 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
HUE041595T2 (hu) * 2012-01-12 2019-05-28 Bioverativ Therapeutics Inc A VIII-as faktorral szembeni immunogenitás csökkentése a VIII-as faktorterápiát kapó egyéneknél
HRP20191920T1 (hr) * 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
CN119192402A (zh) 2012-02-15 2024-12-27 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013155324A1 (en) 2012-04-11 2013-10-17 Biogen Idec Ma Inc. Methods of detecting glycosaminoglycans
EP3693000B1 (en) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Procoagulant compounds
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc Chimeric clotting factors
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
PL2882450T3 (pl) * 2012-07-11 2020-06-29 Bioverativ Therapeutics Inc. Kompleks czynnika viii z xten i białkiem czynnika von willebranda oraz jego zastosowania
EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) * 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
PL2956477T5 (pl) * 2013-02-15 2024-05-27 Bioverativ Therapeutics Inc. Zoptymalizowany gen czynnika viii
EA201890671A1 (ru) * 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. Препараты полипептида фактора viii
US9090697B2 (en) * 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10364288B2 (en) 2013-05-24 2019-07-30 Biogen Ma Inc. Anti-GPIIB/IIIA antibodies or uses thereof
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
CN105592973B (zh) * 2013-06-20 2020-06-19 百特奥尔塔公司 药物动力学药物给药方案设备和方法
AU2014302100B2 (en) * 2013-06-28 2020-02-13 Bioverativ Therapeutics Inc. Thrombin cleavable linker with XTEN and its uses thereof
US20160229903A1 (en) * 2013-06-28 2016-08-11 Biogen Ma Inc. Thrombin cleavable linker
CA3012994C (en) 2013-07-31 2020-10-20 Rinat Neuroscience Corp. Engineered polypeptide conjugates
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
ES2967617T3 (es) * 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
EP3083933A1 (en) 2013-12-20 2016-10-26 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
FI4176894T3 (fi) 2014-01-10 2024-05-29 Bioverativ Therapeutics Inc Kimeerisiä tekijä viii -proteiineja ja niiden käyttötarkoituksia
EP3102589A1 (en) 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2015148454A1 (en) * 2014-03-28 2015-10-01 Asklepios Biopharmaceutical, Inc. Optimized and modified factor viii genes for gene therapy
KR102430829B1 (ko) 2014-04-25 2022-08-09 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
KR102122463B1 (ko) 2014-10-14 2020-06-15 할로자임, 아이엔씨 아데노신 디아미네이즈-2(ada2)의 조성물, 이의 변이체 및 이를 사용하는 방법
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
WO2017070167A1 (en) 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
PT3411478T (pt) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc Genes do fator viii otimizados
BR112018070463A8 (pt) 2016-04-15 2022-08-30 Baxalta GmbH Método e aparelho para prover um regime farmacocinético de dosagem de fármaco
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
KR102175878B1 (ko) * 2016-06-24 2020-11-06 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
US11447542B2 (en) 2016-08-05 2022-09-20 Medimmune, Llc Anti-O2 antibodies and uses thereof
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
KR20190064636A (ko) 2016-10-19 2019-06-10 메디뮨 엘엘씨 항-o1 항체 및 이의 용도
BR112019011198A2 (pt) * 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
CN108239151B (zh) * 2016-12-23 2020-07-03 海门晟斯生物制药有限公司 重组单链人FVIII-Fc融合蛋白及其应用
US10896749B2 (en) * 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
CR20190389A (es) 2017-01-31 2019-11-26 Bioverativ Therapeutics Inc Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
EP3802610A1 (en) 2018-06-05 2021-04-14 Amgen Inc. Modulating antibody dependent cellular phagocytosis
MX2021002792A (es) 2018-09-11 2021-05-12 Amgen Inc Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos.
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
SG11202105880TA (en) 2018-12-06 2021-07-29 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor ix
TW202115127A (zh) 2019-06-19 2021-04-16 美商百歐維拉提夫治療公司 治療血友病及低骨質密度之方法及組成物
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
US12173307B2 (en) 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
KR20250005425A (ko) * 2022-04-28 2025-01-09 조인트 스탁 컴퍼니 "바이오케드" Fviii-bdd 및 이종의 신호 펩타이드에 기반한 융합 단백질을 인코딩하는 단리된 핵산
CN114989307B (zh) * 2022-05-11 2023-08-01 华兰生物工程股份有限公司 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235881A (en) * 1978-12-04 1980-11-25 Cort Joseph H Method for producing high potency factor VIII
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
EP2275557A1 (en) * 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
DE60225118T2 (de) * 2001-02-05 2009-03-05 Novo Nordisk Health Care Ag Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP1644039B1 (en) 2003-06-19 2014-10-01 Genentech, Inc. Compositions and methods for treating coagulation related disorders
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
LT1824988T (lt) 2004-11-12 2017-10-25 Bayer Healthcare Llc Nukreipta į užduotą saitą fviii modifikacija
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007103515A2 (en) 2006-03-06 2007-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
CA2647314A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
RU2573587C2 (ru) * 2008-02-27 2016-01-20 Ново Нордиск А/С Конъюгированные молекулы фактора viii
US8800831B2 (en) 2009-08-19 2014-08-12 Larry A. Gray Multi-purpose rack and method thereof
PL2393828T3 (pl) 2009-02-03 2017-06-30 Amunix Operating Inc. Wydłużone rekombinowane polipeptydy i zawierające je kompozycje
JP5739865B2 (ja) * 2009-03-24 2015-06-24 バイエル・ヘルスケア・エルエルシー 第ｖｉｉｉ因子変異体および使用の方法
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
AU2010325787B2 (en) * 2009-12-06 2016-05-12 Bioverativ Therapeutics Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
KR102110736B1 (ko) * 2011-07-08 2020-05-14 바이오버라티브 테라퓨틱스 인크. Viii 인자 키메라 및 하이브리드 폴리펩타이드, 그리고 이들의 사용 방법
HUE041595T2 (hu) * 2012-01-12 2019-05-28 Bioverativ Therapeutics Inc A VIII-as faktorral szembeni immunogenitás csökkentése a VIII-as faktorterápiát kapó egyéneknél
EA201890671A1 (ru) * 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. Препараты полипептида фактора viii
JP6083911B2 (ja) 2014-12-19 2017-02-22 花王株式会社 吸収性物品

Also Published As

Publication number Publication date
KR20120129882A (ko) 2012-11-28
AU2017268648A1 (en) 2017-12-21
US9241978B2 (en) 2016-01-26
EA025416B1 (ru) 2016-12-30
LT2506868T (lt) 2018-02-26
EP2506868B1 (en) 2017-11-15
AU2010325787B2 (en) 2016-05-12
ES2880038T3 (es) 2021-11-23
AU2021202912B2 (en) 2024-08-01
SG10201907152YA (en) 2019-09-27
CN102791285A (zh) 2012-11-21
AU2016213822A1 (en) 2016-09-01
US20220265780A1 (en) 2022-08-25
JP6062459B2 (ja) 2017-01-18
EP3326643A1 (en) 2018-05-30
EP2506868A4 (en) 2013-07-24
AU2016213822B2 (en) 2017-08-31
EP3906937A1 (en) 2021-11-10
US9050318B2 (en) 2015-06-09
CA3121739A1 (en) 2011-06-09
JP2017025098A (ja) 2017-02-02
IL220204B (en) 2018-08-30
ZA201204874B (en) 2016-06-29
AU2010325787A8 (en) 2012-07-19
BR112012013502A2 (pt) 2017-01-10
AU2024227757A1 (en) 2024-11-21
ME02964B (me) 2018-07-20
KR101770849B1 (ko) 2017-09-05
HRP20211010T1 (hr) 2021-09-17
AU2010325787A2 (en) 2013-06-06
HK1253887A1 (en) 2019-07-05
EP3326643B1 (en) 2021-04-07
IL220204A0 (en) 2012-07-31
US20190262429A1 (en) 2019-08-29
JP5903048B2 (ja) 2016-04-13
RS56957B1 (sr) 2018-05-31
CO6561782A2 (es) 2012-11-15
EP4382170A3 (en) 2024-09-04
NO2506868T3 (el) 2018-04-14
JP2013512678A (ja) 2013-04-18
CY1124888T1 (el) 2023-01-05
JP2018024706A (ja) 2018-02-15
JP2023071969A (ja) 2023-05-23
SG10201408049SA (en) 2015-02-27
SI2506868T1 (en) 2018-04-30
CA2782424A1 (en) 2011-06-09
PT2506868T (pt) 2018-02-23
EP4382170A2 (en) 2024-06-12
MX336830B (es) 2016-02-03
EA201290443A1 (ru) 2013-06-28
DK2506868T3 (da) 2018-01-29
MY159135A (en) 2016-12-15
NZ703153A (en) 2015-02-27
US11266720B2 (en) 2022-03-08
JP6641340B2 (ja) 2020-02-05
WO2011069164A2 (en) 2011-06-09
US20130108629A1 (en) 2013-05-02
ES2659888T3 (es) 2018-03-19
AU2017268648B2 (en) 2019-01-31
MX382693B (es) 2025-03-13
PL3326643T3 (pl) 2021-10-25
PL2506868T3 (pl) 2018-06-29
SG181130A1 (en) 2012-07-30
PT3326643T (pt) 2021-07-12
JP2022051964A (ja) 2022-04-01
US20130274194A1 (en) 2013-10-17
JP7244688B2 (ja) 2023-03-22
JP2020019821A (ja) 2020-02-06
HRP20180135T1 (hr) 2018-04-06
JP6385410B2 (ja) 2018-09-05
JP2015083608A (ja) 2015-04-30
AU2019202969A1 (en) 2019-05-16
NZ600709A (en) 2015-01-30
AU2010325787A1 (en) 2012-07-12
SMT201800099T1 (it) 2018-03-08
IL260769B (en) 2020-03-31
US20160199455A1 (en) 2016-07-14
CA2782424C (en) 2021-07-27
MX2012006347A (es) 2012-10-03
JP2025083451A (ja) 2025-05-30
MX353233B (es) 2018-01-08
WO2011069164A3 (en) 2011-07-28
EA201691109A1 (ru) 2017-01-30
HUE036233T2 (hu) 2018-06-28
EP2506868A2 (en) 2012-10-10
EA038618B1 (ru) 2021-09-23
AU2021202912A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
CY1119919T1 (el) Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii-fc kai meθοδοι χρησης αυτων
CY1122900T1 (el) Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii και μεθοδοι χρησης αυτων
EA201291480A1 (ru) Фактор ix полипептиды и способы их использования
CY1123407T1 (el) Σταθερες υδατικες φαρμακοτεχνικες μορφες της αδαλιμουμαμπης
CY1113713T1 (el) Ανοσοκατασταλτικα πολυπεπτιδια και νουκλεϊκα οξεα
PH12014501360A1 (en) Compositions and methods for modifying a predetermined target nucleic acid sequence
EA201690529A1 (ru) Способы модификации клетки-хозяина
GEP201706773B (en) Cx3cr1-binding polypeptides
DK2229471T3 (da) Stærkt elektrisk ledende overflader til elektrokemiske anvendelser
CY1118215T1 (el) Αντι-νεοπλασματικη ανοσοθεραπεια
DK2831241T3 (da) Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression.
MX2013002709A (es) Moleculas de union a 4-1bb.
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
HK1213521A1 (zh) Fix多肽的應用
IT1396562B1 (it) Metodo e reattore chimico per la produzione di idrocarburi gassosi derivanti da materie plastiche.
CY1115975T1 (el) Ταπενταδολη για τη θεραπεια πονου σε αρθριτιδα
CL2013000534A1 (es) Polipeptido mutante que tiene actividad delta-5 desaturasa; molecula de acido nucleico aislada que lo codifica; célula huesped transformada que expresa el polipeptido.
EA202092566A1 (ru) Фактор ix полипептиды и способы их использования
CY1117137T1 (el) 2-amino-3-methyl-hex-5-enoic acid και η χρηση του στην παραγωγη πεπτιδιων οπως bacitracins
HK1185266A (en) Factor ix polypeptides and methods of use thereof